SCHEMBL4225641

SCHEMBL4225641

CCCCCNC(=O)N(C)c1ccc(C)c(-c2ccc(C=C(OC)C(=O)O)cc2)c1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
QPCT Q16769 1/20 0.36
LTB4R2 Q9NPC1 1/20 0.34
MAPK14 Q16539 3/20 0.34
PPARG P37231 1/20 0.33
PPARD Q03181 1/20 0.33
PPARA Q07869 1/20 0.33
MGLL Q99685 1/20 0.33
RAB9A P51151 2/20 0.33
APP P05067 1/20 0.33
DRD2 P14416 1/20 0.33
ADRA1A P35348 1/20 0.33
DRD3 P35462 1/20 0.33
SMN1; SMN2 Q16637 3/20 0.32
KDM4E B2RXH2 2/20 0.32
LMNA P02545 1/20 0.32
NPC1 O15118 1/20 0.32
ALDH1A1 P00352 1/20 0.32
GAA P10253 1/20 0.32
MAPT P10636 1/20 0.32
HPGD P15428 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4225632 1.00 QPCT (0.36) QPCTLTB4R2MAPK14PPARGPPARD
SCHEMBL4225634 1.00 QPCT (0.36) QPCTLTB4R2MAPK14PPARGPPARD
SCHEMBL4218757 0.94 LTB4R2 (0.34) QPCTLTB4R2MAPK14PPARGPPARD
SCHEMBL4218749 0.94 LTB4R2 (0.34) QPCTLTB4R2MAPK14PPARGPPARD
SCHEMBL4218753 0.94 LTB4R2 (0.34) QPCTLTB4R2MAPK14PPARGPPARD
SCHEMBL2085461 0.87 SMN1; SMN2 (0.36) QPCTLTB4R2MAPK14PPARGRAB9A
SCHEMBL2085465 0.87 SMN1; SMN2 (0.36) QPCTLTB4R2MAPK14PPARGRAB9A
SCHEMBL4215728 0.85 PTGS2 (0.40) LTB4R2RAB9ADRD2ADRA1ADRD3
SCHEMBL4215720 0.85 PTGS2 (0.40) LTB4R2RAB9ADRD2ADRA1ADRD3
SCHEMBL4215727 0.85 PTGS2 (0.40) LTB4R2RAB9ADRD2ADRA1ADRD3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8383652-B2 Biaromatic compounds that modulate PPAR-receptors GALDERMA RESEARCH & DEVELOPMENT (FR) 2013-02-26 US claimed
US-20090012129-A1 NOVEL BIAROMATIC COMPOUNDS THAT MODULATE PPAR-RECEPTORS GALDERMA RESEARCH & DEVELOPMENT (FR) 2009-01-08 US claimed
US-8383652-B2 Biaromatic compounds that modulate PPAR-receptors GALDERMA RESEARCH & DEVELOPMENT (FR) 2013-02-26 US disclosed
US-20090012129-A1 NOVEL BIAROMATIC COMPOUNDS THAT MODULATE PPAR-RECEPTORS GALDERMA RESEARCH & DEVELOPMENT (FR) 2009-01-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090012129-A1 NOVEL BIAROMATIC COMPOUNDS THAT MODULATE PPAR-RECEPTORS PPARG, PPARD, PPARA QPCT 2942/4885LTB4R2 1202/4885MAPK14 2223/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.